Diabetes is a consequential human ailment afflicting a significant population in many countries across the world. In India, it is turning out to be a major health quandary, especially in urban areas. Though there are various approaches to reduce the ill-effects of diabetes and its secondary complications, herbal formulations are preferred due to lesser side-effects and low cost. Traditional medicines derived from medicinal plants are utilized by about 60% of the world's population. This review focuses on Indian herbal drugs and medicinal plants utilized in the treatment of diabetes, especially in India.
1,
2. It is described as an increase in blood glucose levels after consumption of any type of meal. Diabetes results from either insulin deficiency or its malfunctioning 2. According to statistics, 2.8% of the world's population suffers from this disease and it is expected to increase to more than 5.4% by 2025 3 . Diabetes requires early diagnosis, treatment, and lifestyle changes. Diabetes is a disease that affects many people in the 21 st century and is known as the 'fifth' leading cause of death 4 . High prevalence, variable pathogenesis, progressive process, and complications of diabetes all highlight the urgent need for effective treatments. Nowadays, different treatments, such as insulin therapy, pharmacotherapy, and diet therapy, are available to control diabetes. There are several types of glucose-lowering drugs that exert anti-diabetic effects through different mechanisms. These mechanisms include stimulation of insulin secretion by sulfonylurea and meglitinides drugs, increasing of peripheral absorption of glucose by biguanides and thiazolidinediones 5 , delay in the absorption of carbohydrates from the intestine by alpha-glucosidase, and reduction of hepatic gluconeogenesis by biguanides 6 .
Molecular mechanism of insulin signalling
Insulin is an anabolic peptide hormone released by the â-pancreatic islet cells in response to elevated levels of nutrients, such as glucose in the blood supply. Insulin binds to its receptor which belongs to the receptor tyrosine kinase superfamily. It has orthologues in all metazoans on the major insulin-responsive tissues of the body namely skeletal muscle, adipose tissue (where it stimulates glucose transport through translocation of GLUT4), liver (where it promotes glucose storage into glycogen and decreases glucose output), and in most cells where it has pleiotropic effects. The receptor activates a complex intracellular signalling network through Insulin receptor substrates (IRS) termed phosphotyrosine-binding (PTB) domain of adaptor proteins and the canonical PI3K and ERK cascades whose function is to stimulate the transport of nutrients (glucose, amino acids and fatty acids) from the blood supply to tissues and then to promote the conversion of nutrients into storage macromolecules (glycogen, protein, and lipids). Insulin receptor resists a hetero-tetrameric structure (two extracellular á-subunits and two transmembrane â-subunits). When insulin binds to the á-subunits, it activates the â-subunits & these â-subunits auto-phosphorylate themselves on tyrosine residues. Basically, once the â-subunits are phosphorylated they get activated and lead to the phosphorylation and activation of insulin receptor substrate (IRS1/2). IRS1/2 activation and dephosphorylation is regulated by a protein called p10 or phosphatase intense and homologue effaced from chromosome 10. This is a negative regulator of pip3 that results in dephosphorylation of pip3. The PI3K-AKT pathway, mostly responsible for the metabolic insulin action via the translocation of the glucose transporter type 4 (GLUT4) vesicles to the plasma membrane, which, in turn, allows the glucose uptake in muscle cells and adipocytes. PI3K or tri phosphatidylinositol 3 kinase protein binds to IRS1/2 through its p85 subunit, the PI3K protein will phosphorylate pip2 or Phosphatidylinositol 4,5-bisphosphate to pip3 or Phosphatidylinositol (3,4,5)-trisphosphate. When pip3 concentration increases, it recruits & activates other proteins (PDK1 & AKT or protein kinase B) towards the plasma membrane. After activation of PDK1, it will phosphorylate AKT. When insulin concentrations are low, insulin sensitive cells have reservoirs of vessels (intracellular vesicles) that contain glucose conveyors embedded in the cytoplasmic vesicles (GLUT 4), which moves towards the plasma membrane with the avails of the protein called AS160. GLUT4 -glucose transporters are present in a vesicle, but they are useless for transporting glucose. After inhibition of glucose through vascular translocation & insulin stimulation, AKT will phosphorylate and inactivate AS160 which will allow translocation to occur. Glucose transporter will get embedded into a cellular membrane after vascular translocation. AKT phosphorylates other proteins like GSK3 or glycogen synthase kinase 3 & it will allow inhibition of GSK3 which is a kinase inactivates GS or glycogen synthase (an important enzyme involved in glycogen synthesis) after GSK3 phosphorylates GS. The TSC1/2-mTOR pathway, playing a critical role in protein synthesis since the mammalian target of rapamycin (mTOR) is a central controller for several anabolic and catabolic processes including RNA translation, ribosome biogenesis and autophagy, in response not only to growth factors and hormones like insulin but also to nutrients, energy and stress signals.GLUT4 allows glucose to get into the cell where glucose can undergo glycolysis. AKT not only allow glucose to enter the cell & undergo glycolysis but it's also activating glycogen synthesis (to store glucose which is in the cell). AKT activates mTORC1 or mammalian target of rapamycin complex 1, including steps like tuber sclerosis complex, reb proteins, etc. After activation of mTORC1, it will activate its downstream target -P70S65 kinase through phosphorylation. P70S55 negatively inhibit IRS proteins by phosphorylating IRS on serine residues. This is how the insulin signalling is controlled by negative feedback inhibition. GLUT4 localisation in the plasma membrane is entirely dependent on the presence of insulin and activation of insulin receptor so when insulin is dislodged from the insulin receptor, GLUT4 is taken back up into vesicles which contain them for the next time the cells stimulated by insulin. There is some tissue that does not require insulin for efficient uptake of glucose: for instance -the brain and the liver. This is because these cells don't use GLUT4 for importing glucose, but use another transporter that is not insulin-dependent. The insulin signalling pathway (ISP) is an important biochemical pathway, which regulates some fundamental biological functions (glucose and lipid metabolism, protein synthesis, cell proliferation, cell differentiation and apoptosis). Minkowski. They found that upon complete removal of the pancreas from dogs, the dogs exhibited all the signs and symptoms of diabetes and died shortly afterwards [7] . 1910 Sir Edward Albert Sharpey-Schafer of Edinburgh in Scotland suggested that diabetics lacked a single chemical which was normally produced by the pancreas. Name of this chemical was later proposed to be insulin [7] . 1921 Frederick Grant Banting and Charles Herbert Best repeated the work of Von Mering and Minkowski but went a step further and managed to show that they could reverse the induced diabetes in dogs by giving them an extract from the pancreatic islets of Langerhans of healthy dogs. This was a step forward in elucidation of the endocrine role of the pancreas in metabolism and existence of insulin [8] . 1922 Scientists proceeded on to isolate insulin from bovine pancreases at the University of Toronto in Canada, thereby leading to the availability of an effective treatment of diabetes mellitus, with the first clinical patient being treated [7] . 1935 The distinction between what is now known as type I and type II diabetes was made by Sir Harold Percival (Harry) Himsworth [7] . 
Molecular mechanism & genetics affected in diabetes mellitus
Diabetes is controlled by lowering the hepatic glucose production. It is a primary therapeutic strategy to control diabetes. Increased hepatic glucose production in diabetic states may occur as a consequence of insulin deficiency or insulin resistance that impairs glucose uptake in multiple organs. Most of the strategies employed to reduce hepatic glucose production in diabetes are associated with stimulation of the energy sensor enzyme AMPK (adenosine monophosphateactivated protein kinase), which is normally activated by an elevated AMP to ATP ratio to block cellular anabolism (i.e., gluconeogenesis, lipogenesis, glycogen synthesis). AMPK is taken into account as a master switch regulating glucose and macromolecule metabolism. The AMPK is an enzyme that works as a fuel gauge, being activated in conditions of high energy phosphate depletion. AMPK is additionally activated robustly by muscle contraction and heart muscle anaemia and is concerned within the stimulation of glucose transport and carboxylic acid-reaction made by these stimuli. In the liver, activation of AMPK ends up in increased fatty acid reaction and reduced production of glucose, cholesterol, and triglycerides. The two leading diabetic medications, namely -metformin and rosiglitazone, show their metabolic effects partly through AMPK. The amp-stimulated enzyme, AMPD2, is a natural counter-regulator of AMPK and its activation in the liver of diabetic mice is associated with reduced AMPK activity. Diabetes Type-1 risk is increased by certain variants of the HLA-DQA1, HLA-DQB1, and HLA-DRB1 genes. These genes provide instructions for making proteins that play a critical role in the immune system. They belong to a family of genes called the Human Leukocyte Antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria. Diabetes Type-2 arises when pancreatic â-cells fail to secrete sufficient insulin, because of acquired â-cell secretory dysfunction or decreased â-cell mass. â-cell mass plays a vital role in determining whether an individual will progress to diabetes. These defects may be caused by primary â-cell defects, such as the one seen in the monogenic diabetes forms of MODY (Maturity-Onset Diabetes of the Young), or by secondary â-cell defects, caused by glucotoxicity, increased free fatty acids, cytokines, mitochondrial dysfunction or metabolic stress. Genetic factors -After the explanation of Mendelian disorders with diabetes as a major • 1922, First exogenous insulin admistered to human.
• 1923 , Insulin (Iietin) commercially available in the United States.
• 1936 , the first commercially avail¬able, extended-action insulin, PZI (protamine zinc insulin), was released.
• 1946 , the Nordisk Insulin Laboratory in Denmark released the second extended-action insulin, NPH (neutral protamine Hagedorn).
• 1956 , First commericially available SU in United States.
• 1959 , Metformin was introduced (outside United States; introduced to united states).
• 1983 , Recombinant human insulin.
• 1984 , Second -generation SUs.
• 1995 , First AGI (acarbose).
• 1996 , First TZD (troglitazone).
• 1997 , First meglitinide (repaglinide).
• 2005 , First amylin agonist (pramlintide).
• 2006 , First DPP-4 inhibitor (sitagliptin).
• 2008 , Colesevelam approved for diabetes.
• 2009 , Bromocriptine aproved for diabetes.
• 2013 , First SGLT-2 inhibitor (canagliflozin).
phenotypic feature, it has become clear that type-2 diabetes is heterogeneous and may result from defects in one or more molecular pathways. Genetic defects of the â-cell usually referred to as Maturity-Onset Diabetes of the Young (MODY), can result from mutations in any of at least six different genes. Most of the MODY subtypes are caused by mutations in transcription factors, which are involved in the tissue-specific regulation of gene expression in the liver and in pancreatic beta-cells. Other related genetic factors are due to insulin receptor mutations. Gene variants may impair insulin action in the insulin target tissues muscle, fat and liver.
Management of diabetes mellitus
Lifestyle management is apparently the cornerstone of management of diabetes mellitus. It is recognized as the essential part of diabetes prevention. Meta-analyses demonstrate that manner interventions, as well as diet and physical activity, led to a 63% reduction in polygenic disorder incidence in those at high risk. Lifestyle modification programs have incontestable encouraging improvement in risk factors for diabetes; but, the impact on diabetes incidence has not been reportable. The dietary management of diabetes could be a complement of lifestyle management. It's a positive impact on future health and quality of life. Dietary management aims at best metabolic management by establishing a balance between food intake, physical activity, and drugs to avoid complications. In type-2 diabetes, the dietary objective is for improved glycemic and macromolecule levels and weight loss as acceptable. Plant-derived medications have additionally found vast use within the management of diabetes.
Diabetic Complications Acute complications
These types of complications include diabetic ketoacidoses (DKA) and non-ketotic hyperosmolar state (NKHS). While the first is seen primarily in individuals with type-1 diabetes mellitus, the latter is prevalent in individuals with type-2 diabetes mellitus. In DKA, sickness and retching are frequently present. Torpidity and focal sensory system gloom may develop into a trance-like state in extreme DKA. Cerebral oedema, a genuine complication, is usually seen in youngsters. NKHS is generally found in older people. NKHS is most commonly seen in elderly individuals with type-2 diabetes mellitus.
Chronic complications
The chronic complications of diabetes mellitus affect many organ systems and are responsible for the majority of morbidity and mortality. Chronic complications can be divided into vascular and nonvascular complications.
Therapeutics of Diabetes mellitus Caloric content
Most patients with non-insulin dependent diabetes mellitus (NIDDM) are overweight or obese, and it is now well-recognized that this is a major factor in insulin resistance. When extreme caloric restriction and/or rapid weight loss seem desirable, a very low-calorie diet or protein-sparing modified fast may be considered. Reduction of excess weight is a primary component in the management of NIDDM.
Macronutrients
The ideal balance of carbohydrate, protein, or fat intake in patients with NIDDM is still a matter of discussion. It has recently been recognized that a diet containing 60% carbohydrates, even if not including sugar, may predispose to the development of dyslipidemia. Protein intake should not exceed the daily requirement since high protein intake appears to have a detrimental effect on renal function.
Physical activity and exercise
Recent clinical investigations have shed light on the mechanism by which exercise may help in controlling excessive blood glucose levels. Regular exercise improves insulin sensitivity and, as a consequence, may improve glucose tolerance. Such effects are beneficial in patients with type-2 diabetes since they enhance work capacity and quality of life and may also help to reduce the requirement for insulin or oral hypoglycemic agents.
ConClusion
Plant drugs and herbal formulations are considered to be less toxic and free from sideeffects than synthetic ones. Based on the WHO recommendations, hypoglycaemic agents of plant origin used in medicine are important. By 2025, it is predicted the majority of diabetes -positive people of developed countries will be age of 45 -64 and will be affected in their most productive years in developing countries. In general, there is very little biological erudition on the categorical modes of action in the treatment of diabetes, but most of the plants have been found to contain substances like glycosides, alkaloids, terpenoids, flavonoids etc. that are frequently implicated as having antidiabetic effects. The research for alternate remedies from the plant kingdom for diabetes mellitus will continue all over the world as the dreaded disease poses many challenges not only to the physician but also to the researcher.
